Beta Bionics, Inc. SEC Filings

Beta Bionics, Inc. Form 144 shows a proposed sale of 4,982 common shares through Merrill Lynch on 10/03/2025 with an aggregate market value of $108,076.24. The filing identifies prior insider sales by Stephen Feider in the past three months, including a 15,018-share trade on 10/01/2025 that generated $311,836.91 and other sales dated 09/08/2025, 09/05/2025, 08/22/2025, and 08/19/2025. The securities to be sold were acquired via stock options on 10/03/2025 and the filing indicates payment was made in cash on 10/01/2025. The seller represents there is no undisclosed material adverse information. The filing supplies transaction details but does not include the issuer's SEC file number, issuer address, or the filer CIK.

Insider sale notice for Beta Bionics, Inc. (BBNX): The filer reports a proposed sale of 15,018 common shares with an aggregate market value of $311,836.91 to be executed on 10/01/2025 on NASDAQ. The filing states the shares were acquired on 10/01/2025 through stock options granted by the issuer and paid for in cash.

The filing also discloses four recent transactions by the same seller totaling 20,000 shares sold between 08/19/2025 and 09/08/2025 with combined gross proceeds of $331,831.80. The filer certifies no undisclosed material adverse information and includes broker details for the planned sale.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed a shared, non‑sole beneficial ownership of 2,286,728 shares of Beta Bionics, Inc. common stock, representing 5.3% of the class. The filing on a Schedule 13G indicates the stake is reported under passive ownership rules, with no sole voting or dispositive power claimed and shared voting and dispositive power of 2,286,728 shares. Addresses and citizenships of the reporting persons are provided and a Joint Filing Agreement is attached.

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options and completed an offsetting sale on 09/08/2025. He exercised 9,900 options with an exercise/conversion price of $5.10 per share, resulting in acquisition of 9,900 shares underlying the option.

The same day Mr. Feider sold 9,900 shares pursuant to a Rule 10b5-1 plan adopted May 15, 2025, at a weighted average sale price of $21.12648 per share (range $21.00–$21.2933). After these reported transactions he beneficially owned 44,041 shares of common stock and reported 89,695 derivative securities beneficially owned.

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported multiple option grants and open-market sales on 09/04/2025 and 09/05/2025. The filings show option awards exercisable at $5.10 and acquisitions of underlying common stock: 656, 4,093 and 11,411 option shares were added, increasing option holdings to 66,428; 33,136; and 21,725 respectively. Concurrently, 18,229 common shares were sold under a Rule 10b5-1 plan (6,818 at a weighted average $19.9736 and 11,411 at $20.564162). Following these transactions Hopman directly beneficially owned 31,215 common shares. Vesting schedules for the options are specified, with some vesting monthly from 09/14/2023 and others following a one-year cliff from 03/20/2023.

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 09/05/2025. He exercised an employee stock option to acquire 100 shares at an exercise price of $5.10 and simultaneously sold 100 shares at $21.00 pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. After these transactions he beneficially owned 44,041 shares of common stock directly.

The option exercised was part of an employee stock option award exercisable beginning in September 2023 and expiring 09/13/2033; the filing shows 99,595 derivative securities (options) beneficially owned following the reported transactions. The form is signed and dated 09/08/2025.

Form 144 notice for Beta Bionics, Inc. (BBNX): The filing reports a proposed sale of 9,900 common shares through Merrill Lynch on 09/08/2025 on NASDAQ with an aggregate market value of $209,152.15. The shares were acquired the same day as stock options from the issuer and paid in cash. The filing lists total shares outstanding as 43,470,125. Recent insider sales by Stephen Feider are included: 1,497 shares on 06/02/2025 for $26,783.06; 5,587 on 08/19/2025 for $95,171.78; 4,413 on 08/22/2025 for $75,082.65; and 100 on 09/05/2025 for $2,100.00. Several standard filer and issuer identifier fields are blank in the provided content.

Beta Bionics, Inc. (BBNX) Form 144 notifies a proposed sale of 11,411 common shares through Merrill Lynch with an aggregate market value of $234,656.73, scheduled approximately for 09/05/2025 on NASDAQ. The filing shows the shares were acquired the same day as a stock option exercise and paid in cash. The filer (person for whose account the shares will be sold) recorded prior open-market dispositions in the past three months totaling 23,844 shares for gross proceeds of $420,084.80 on 06/02/2025, 08/19/2025 and 09/04/2025. The notice includes the required signature representation about absence of undisclosed material information.

Form 144 notice for Beta Bionics, Inc. (BBNX) shows a proposed sale of 100 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $2,100. The filing identifies the shares as acquired on 09/05/2025 by exercise of stock options from the issuer and paid in cash the same date. The filer has executed several recent open-market sales: 4,413 shares on 08/22/2025 for $75,082.65, 5,587 shares on 08/19/2025 for $95,171.78, and 1,497 shares on 06/02/2025 for $26,783.06. The notice includes the standard representation that the seller attests not to possess undisclosed material adverse information.